The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

Zai Lab (ZLAB) “announced that China’s National Medical Products Administration has accepted the Biologics License ...

Hailed as the first Chinese company to launch a homegrown antibody drug conjugate (ADC), RemeGen has recently been battling a ...

Zilovertamab vedotin is Merck’s investigational antibody-drug conjugate (ADC) that targets receptor tyrosine kinase-like orphan receptor 1 (ROR1). Global recruitment of the waveLINE-010 trial ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial cancer, said Evangelia Vlachou, MD, of Johns Hopkins Medicine. While ...

The addition of brentuximab vedotin to lenalidomide and rituximab improved survival for certain patients with DLBCL. A similar percentage of patients in each arm experienced treatment-emergent ...

The therapy includes brentuximab vedotin, lenalidomide, and a rituximab product, targeting patients who failed two or more prior systemic therapies. Approval is based on the phase 3 ECHELON-3 ...

Results also show that reducing the Padcev dose at treatment initiation may benefit older patients with urothelial carcinoma, a type of bladder cancer.

Overall survival was significantly improved in patients treated with brentuximab vedotin plus lenalidomide/rituximab compared with placebo plus lenalidomide/rituximab ...

Results showed enfortumab vedotin plus pembrolizumab reduced the risk of death by 49% versus chemotherapy. The median OS was 33.8 months for the combination versus 15.9 months for chemotherapy.